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Background/aim: Vitiligo is a common depigmenting disorder. The damage can also occur in similar ways to melanocytes within other
organs. We evaluated the brainstem and auditory pathway functions by evaluating brainstem auditory evoked potentials (BAEPs) and
whether there is any relationship between auditory functions and autoimmunity.
Materials and methods: Forty patients with vitiligo and 20 healthy volunteers were enrolled. Thyroid functions and autoantibodies were
examined and BAEP tests were assessed by a neurologist.
Results: Antithyroid peroxidase (anti-TPO) and antithyroglobulin (anti-TGA) antibody positivity was higher in the patient group (P <
0.05). A negative correlation was detected between anti-TPO and lead III, IV, and V latency and I–III interpeak latency (IPL) of the right
ear together with lead IV latency and I–V IPL of the left ear in the patient group. When each BAEP parameter was compared between
the two groups, more abnormalities were detected in the V latency and III–V IPL of the left ear together with IV and V latency of the
right ear.
Conclusion: In this study the presence of a correlation between increased anti-TGA and anti-TPO levels and BAEP parameters may be
related to an autoimmune-mediated mechanism. However, further studies are needed to be performed in a large patient series.
Key words: Brainstem auditory evoked potentials, thyroid autoimmunity, vitiligo

1. Introduction
Vitiligo is a relatively common disease occurring as a
result of functional melanocyte loss (1). The embryonic
origin of human melanocytes is derived from the neural
crest and is located in the epidermis, hair bulbs of the skin,
the uveal tract and the retinal pigment epithelium of the
eye, the inner ear, and the leptomeninges (2). Although the
loss or reduction of melanocytes in the inner ear may have
a critical effect on hearing, patients with vitiligo usually
do not have remarkable audiological abnormalities. There
have been few studies on hearing loss in vitiligo patients in
different populations (2–7).
Vitiligo is a chronic acquired pigmentation disorder
that occurs as a result of loss of functional melanocytes
from the epidermis and hair follicles, clinically
characterized by depigmented patches (8). Melanocyte
is a critical cell to maintain normal functioning of the
* Correspondence: karadagaserap@gmail.com

stria vascularis and cochlea. It is essential for hair cells,
as well (6,9). In animal trials, it has been shown that low
melanin levels in the cochlea may increase the tendency
to develop auditory fatigue, noise-induced hearing loss,
and audiogenic seizures (3). Abnormal brainstem auditory
evoked potentials (BAEPs) were recorded in patients
with albinism. Therefore, changes in pigment cells or
melanocyte destruction can cause hearing problems (10).
A BAEP is a short-latency auditory evoked potential
recorded with surface electrodes. The potentials have series
of positive and negative waves that are recorded within
10 ms following the stimulus. BAEPs are useful to assess
the lower auditory system and may be helpful to detect
subclinical abnormalities in the auditory system (11).
Vitiligo is an autoimmune-mediated disease. Thyroid
disease is the most common autoimmune disease that
is accompanied by vitiligo. Several studies have shown
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that the frequencies of autoimmune thyroid diseases or
abnormal thyroid tests are significantly higher in patients
with vitiligo than control groups (12–14).
There are limited studies assessing hearing
abnormalities in vitiligo patients in the literature and their
results are controversial. Most patients with vitiligo are
asymptomatic for audiological abnormalities (2–4,6). To
date, an association between hearing loss and autoimmunity
has not been assessed yet. Thus, we aimed to evaluate
and identify possible subclinical electrophysiological
abnormalities of the auditory system with BAEP testing in
patients with vitiligo as well as the relationship between
BAEP results and autoimmune thyroid diseases.
2. Materials and methods
2.1. Patients and controls
Forty patients with generalized vitiligo and 20 healthy
volunteers of similar age and sex were enrolled in our
study. The diagnosis was made based on medical history,
physical examination, and Wood lamp examination
without the need of biopsy in all cases. The study received
ethics committee approval and written informed consent
was obtained from all participating individuals. BAEP
examinations for both ears were performed in the patient
group and in the control group.
Patients who had history or evidence of audiological
diseases; familial hearing loss; chronic noise exposure;
head trauma; metabolic, neurological, vascular, or
autoimmune disease; any systemic diseases such as
diabetes or hypertension; age >50 years; or use of oral
autotoxic or corticosteroids were excluded from the study.
2.2. Laboratory tests
Blood samples were analyzed for thyroid function assays
and detection of thyroid autoantibodies. Free T3, free
T4, thyroid-stimulating hormone (TSH), thyroglobulin,
antithyroglobulin (anti-TGA), and antithyroid peroxidase
(anti TPO) antibody levels were measured by immunoassay
of hormones. Laboratory tests were measured with the
ARCHITECT i4000SR Immunoassay Analyzer (Abbott).
2.3. Measurement of BAEPs
BAEPs were measured by using the Nihon Kohden
Neuropack 2 EMG/EP measuring system and two
recording channels with filter band-pass between 100 and
3000 Hz. This were based on the American EEG Society
guidelines (15). Recording electrodes were attached on
the vertex (Cz), mastoids, and a frontal location midway
between the nasion and vertex (ground). During testing,
all subjects reclined in a dark and quiet room. Monaural
rarefaction clicks (90 dB, 0.1 ms in duration) were used as
auditory stimuli. White noise at 40 dB to the contralateral
ear was used. The sounds were produced by activating
earphones with pulses of 0.1 ms at a rate of 8–10/s and

954

an intensity of 70 dB above sensation level for the click.
Analysis time was 100 ms with a system band-pass of 100–
200 Hz. I, III, and IV wave latencies; amplitudes; and I–III,
III–IV, and I–V interpeak latencies (IPLs) were measured
and compared between the groups for each ear.
2.4. Evaluation of BAEPs
The increase of latencies and IPLs and the increase or
decrease in amplitudes was considered as an abnormal.
Prolongation in I–III IPL indicates a conduction defect
in the pathway from the proximal eighth nerve into the
inferior pons, increase in III–IV IPL indicates a defect
between the midbrain and pons, and increase in I–V
IPL indicates a defect from the peripheral cochlea to
inferior colliculus (16). The first peak latency is primarily
associated with the basilar membrane and hair cells in
the cochlea. I–III IPL is related with transmission of the
action potentials from the cochlear nucleus to the superior
colliculus (3).
2.5. Statistical analysis
For statistical analysis, SPSS 13.0 (SPSS Inc., Chicago,
IL, USA) was used. Descriptive statistics such as mean,
median, standard deviation, and minimum and maximum
values were used for continuous variables while numbers
and percentages were used for categorical variables. The
Mann–Whitney U test was used to compare two groups
with continuous variables. To determine the relationship
between these variables the Spearman correlation
coefficient was used. Categorical variables were compared
between groups with a chi-square test. P < 0.05 was
considered to be statistically significant.
3. Results
The vitiligo group consisted of 17 females and 23 males
with a mean age of 25 ± 9.38 years (range: 18–51), while
the control group consisted of 7 females and 13 males with
a mean age of 30 ± 8.15 years (range: 18–45 years). There
were no statistically significant differences among groups
with respect to age and sex (P > 0.05). Mean duration of
the disease was 36 ± 73.94 months.
When each BAEP parameter was compared between
the groups, there were statistically significantly more
abnormalities in the vitiligo group in left V, left III–V, right
IV, and right V parameters than in the control group (Table
1). The comparisons of differences in abnormal latency
shifts showed statistically significantly more abnormalities
in the vitiligo group than the control group (P = 0.04,
Table 2). There were no statistically significant differences
in decrease in amplitudes or increase in latencies and IPLs
between the groups (P > 0.05).
When all thyroid parameters were measured, antiTPO and free T4 values were statistically significantly
higher and thyroglobulin values were lower in the vitiligo
group than the control group (P = 0.038, P = 0.029, and P
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Table 1. Comparison of BAEP and laboratory characteristics of study and control groups. Data with
normal and skewed distributions are shown as mean ± standard deviation (SD).
Patients, mean ± SD group

Control group, mean ± SD

P-value

1.59 ± 0.21

1.61 ± 0.24

0.718

R III

3.75 ± 0.26

3.8 ± 0.42

0.559

RV

5.66 ± 0.27

5.65 ± 0.35

0.879

R I–V

4.08 ± 0.38

3.85 ± 0.83

0.157

R I–III

2.19 ± 0.34

2.18 ± 0.38

0.947

R III–V

1.90 ± 0.27

1.84 ± 0.33

0.487

R II

2.66 ± 0.33

2.79 ± 0.45

0.240

R IV

4.86 ± 0.31

4.80 ± 0.51

0.573

Left (L) I

1.61 ± 0.21

1.60 ± 0.29

0.967

L III

3.79 ± 0.29

3.78 ± 0.44

0.913

LV

5.69 ± 0.39

5.69 ± 0.17

0.981

L I–V

4.09 ± 0.34

4.09 ± 0.27

0.892

L I–III

2.24 ± 0.28

2.18 ± 0.37

0.453

L III–V

1.89 ± 0.31

1.91 ±0 .49

0.841

L II

2.59 ± 0.31

2.63 ± 0.45

0.691

L IV

4.83 ± 0.20

5.05 ± 0.39

0.08

Anti-TGA

51.52 ± 17.2

2.66 ± 3.46

0.172

Anti-TPO

114.84 ± 28.2

7.37 ± 3.24

0.038

Thyroglobulin

10.68 ± 11.32

19.55 ± 13.17

0.004

TSH

1.63 ± 1.08

1.37 ±0.79

0.323

Free T3

3.37 ± 1.66

2.99 ± 0.58

0.230

Free T4

1.25 ±0.40

1.07 ± 0.15

0.029

Right (R) I

Abbreviations: TSH, thyroid-stimulating hormone; anti-TGA, antithyroglobulin antibody; anti-TPO,
antithyroid peroxidase antibody.
Normal values of BAEP parameters: I–III interpeak latencies ≥2.5 ms, III–V interpeak latencies ≥2.4 ms,
I–V interpeak latencies ≥4.5 ms.

= 0.04, respectively). The rate of anti-TGA positivity was
statistically significantly higher in the vitiligo group than
the control group (P = 0.024). There were no statistically
significant differences in the other parameters between the
two groups (P = 0.769, Table 1).
We analyzed the degree of correlation between BAEP
parameters and thyroid autoantibodies. A statistically
significant negative correlation coefficient (R = –0.348)
(34.8%) was obtained between anti-TPO and right III
(P < 0.05). Moreover, there was a statistically significant
negative correlation between anti-TPO and right V,
right I–III, right IV, left I–V, and left IV parameters (R =

–0.386, –0.375, –0.541, –0.332, and –0.443, respectively)
(P < 0.05). A negative correlation was found between
anti-TPO and other BAEP parameters, but it was not
statistically significant (P > 0.05). A statistically significant
negative correlation was found between anti-TGA and
right I–III, right IV, and left III parameters (R = –0.336,
–0.353, and –0.331, respectively) (P < 0.05). All the other
BAEP parameters showed negative correlations with antiTGA, except for two parameters, but none of them were
statistically significant. A statistically significant negative
correlation (31.6%) was found between the left III–V
parameter and free T3 (P < 0.05). A significant correlation
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Table 2. Comparison of abnormal cases of BAEP parameters in study and control groups.
Patient group

Control group

P-value

Normal

Abnormal

Normal

Abnormal

RI

37

3

17

3

0.40

R II

37

3

16

4

0.20

R III

40

0

19

1

0.30

R IV

33

7

19

1

0.05

RV

32

8

19

1

0.03

R I–III

40

0

20

0

0.99

R III–V

39

1

20

0

0.31

R I–V

40

0

20

0

0.99

LI

38

2

17

3

0.25

L II

35

5

16

4

0.46

L III

35

5

18

2

0.76

L IV

29

11

16

4

0.510

LV

32

8

19

1

0.032

L I–III

38

2

20

0

0.14

L III–V

36

4

20

0

0.035

L I–V

38

2

20

0

0.147

Table 3. A comparison of BAEP studies in the literature.
LI

LIII

LV

LI–III

LIII–V

LI–V

Aydogan et al. (6)

N

↑(bilaterally)

↑(right)

↑(bilaterally)

N

N

Nikiforidis et al. (2)

↓

N

N

↑

N

N

Özüer et al. (3)

N

N

N

N

N

N

Hong et al. (1)

↓

N

N

↑

N

↑

Shalaby et al. (7)

N

N

N

N

N

N

Elsaied et al. (5)

N

↑(left)

N

↑(left)

↑ (right)

↑(left)

Hong et al. (1)

↓

↑

N

↑

N

N

Our study

N

N

N

N

N

N

AI

AIII

N

N

L: Latency, A: amplitude.

was not observed between other thyroid parameters
(TSH, free T4, thyroglobulin) and BAEP parameters.
Neither thyroid parameters nor BAEP parameters were
significantly correlated with the duration of the disease,
age of patients, or age at disease onset.
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4. Discussion
The results of several studies on audiological abnormalities
in vitiligo were controversial. In some of these studies,
hearing abnormalities were evaluated by pure-tone
audiometry (4,6,7). In other studies, BAEPs were measured
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to examine auditory pathway abnormalities (2,3). Tosti et
al. detected sensorineural hypoacusis in 16% of 50 patients
with vitiligo (4). Sharma et al. found that the hypoacusis
rate was significantly higher in the vitiligo patients than
the control group (17). In Nikiforidis et al.’s study, 12.3% of
vitiligo patients had audiological abnormalities (2).
BAEP studies performed in vitiligo patients
demonstrated various results in the literature. The results
of those studies are shown in Table 2. Elsaied et al.’s study
showed a statistically significant increase both in left
ear third latency (P = 0.04) and in interpeak I–III and
interpeak I–V latencies (respectively, P = 0.001 and 0.04).
In addition, a statistically significant increase in right ear
III–V IPL was noted in the vitiligo patients compared to
the control group (P = 0.02) (5). In Hong et al.’s study, a
significant decrease in peak I latency and a significant
increase in third peak latency and I–III IPL were seen
in the patients with vitiligo (1). It was postulated that a
decrease in first peak latency might be due to decreased
number or activity of inner ear melanocytes in vitiligo
patients (1). Nikiforidis et al. demonstrated that there
were more statistically significant decreases in first peak
latency and more statistically significant increases in I–III
IPL in patients with vitiligo than the control group. The
authors argued that a decrease in first peak latency might
be related to a decrease in numbers of melanocytes in the
inner ear and an increase in I–III IPL might be related
to abnormal synaptic activity and transmission from the
cochlear nerve towards the superior colliculus and delayed
action potential synchronization in the nucleus (2).
In a few studies, pure-tone audiometry and BAEP
results were assessed together. In Özüer et al.’s study,
4% audiological problems were detected in their patient
group, but no statistically significant differences in latency,
IPL, or amplitudes were detected between the patients with
vitiligo and the control group (3). In Aydogan et al.’s study,
sensorineural hypoacusis was detected with audiological
tests in 14% of the patients with vitiligo. Increased third
peak latency and I–III IPL in both ears and increased V
peak latency in the right ear were detected in the patients
with vitiligo compared to the control group. There were no
differences in other latencies or IPLs between the groups
(6). In Shalaby et al.’s study, no statistically significant
differences in BAEP results or pure-tone audiometry
results were detected among the vitiligo and control
groups (7).
In our study, the frequencies of prolonged latency and
IPL and of decreased amplitudes were higher in the vitiligo
group than the control group. No statistically significant
differences in mean values of BAEP parameters were
detected in our study; these findings were similar to the
previous studies performed by Özüer et al. and Shalaby
et al. (3,7). However, the number of abnormal results in

BAEP parameters including left V, left III–V, right IV,
and right V was statistically higher in the patient group
than the control group. These waves may indicate the
electrophysiological abnormalities between the olivary
nucleus in the pons and inferior midbrain. Differences
between studies may be related to the complex and
multifactorial pathogenesis of vitiligo, residual melanocyte
numbers in the inner ear, personal sensitivity, and
coexistence of other immunological diseases.
Vitiligo is an autoimmune-mediated disease. The
frequency of autoimmune diseases including thyroid
disease, pernicious anemia, Addison disease, chronic
urticaria, alopecia areata, psoriasis, asthma, systemic
lupus erythematous, multiple sclerosis, myasthenia
gravis, inflammatory bowel disease, scleroderma, Sjögren
syndrome, and type I diabetes mellitus is higher in patients
with vitiligo than the normal population (18–20). The most
common autoimmune disease accompanied by vitiligo is
thyroid disease. In several studies, autoimmune thyroid
disease and abnormal thyroid tests are more frequently
seen in patients with vitiligo than control groups (12–14).
Anti-TPO is a sensitive marker for early diagnosis
of subclinical autoimmune thyroid disease, evaluation
of immunotherapy response, and detection of high-risk
individuals for autoimmune thyroid disease (21). In our
study, the presence of thyroid autoantibodies (anti-TPO
and anti-TGA) was statistically significantly higher in the
patients with vitiligo than the control group (P = 0.042),
compatible with previous studies (12,13,22).
Hashimoto thyroiditis (HT) is one of the most common
autoimmune endocrine disorders and is characterized
by the presents of antibodies against anti-TPO and/or
antibodies against thyroglobulin (23,24). Hashimoto
encephalopathy is a rare but well-known complication of
HT and is associated with elevated antithyroid antibodies.
HT presents with various neurological manifestations
such as altered mental status, agitation, refractory
seizures, status epilepticus, or cognitive decline (23–25).
Although the exact pathogenesis is still unknown, elevated
antithyroid antibodies can affect the nervous system
seriously (26,27). Hearing pathways are also sensitive
pathways of the central nervous system and are vulnerable
to various metabolic and toxic disorders (23,27). Gawron
et al. showed that there was a positive correlation between
the blood concentration of anti-TPO and the extent of
the disturbances in the central part of the hearing organ.
They pointed out the possible presence of subclinical
Hashimoto encephalopathy affecting the central part of
the auditory organ (28). Sharma et al. assessed the auditory
pathway by BAEPs in 25 newly diagnosed patients with
subclinical hypothyroidism and healthy sex- and agematched controls. The prolongation of wave V in BAEPs
of both ears suggested that the central auditory pathway
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is affected significantly in subclinical hypothyroid patients
(29). Since antithyroid antibodies can affect other parts of
the nervous system, they may affect hearing pathways, as
well. BAEP parameters are a sensitive way to determine
hearing system function. The correlation between BAEP
parameters and antithyroid antibodies can give an idea
about their effects on hearing pathways.
In this study, we also assessed the correlation between
thyroid gland-related parameters indicating autoimmunity
and BAEP parameters. To date, this correlation was not
studied before. The correlation of anti-TPO and BAEP
results showed that when anti-TPO increased, right
III decreased in 34.8% of the measurements (negative
correlation; statistically significant (P < 0.05)). There were
also negative correlations between anti-TPO and right V,
right I–III, right IV, left I–V, and left IV (respectively 38.6%,
37.5%, 54.1%, 33.2%, and 44.3%), which were statistically
significant (P < 0.05). There were negative correlations
between anti-TGA and BAEP parameters including right
I–III, right IV, and left III (respectively R = –0.336, –0.353,
and –0.331), which were statistically significant (P < 0.05).
There was a statistically significant negative correlation
between serum T3 and left III–V parameters (31.6%; P
< 0.005). Lastly, no statistically significant negative or

positive correlations among other thyroid parameters
including TSH and serum T4 and BAEP parameters were
detected in this study.
The presence of a correlation between elevated
anti-TGA and anti-TPO levels and BAEP parameters
demonstrates that abnormal BAEP parameters may be
related to an autoimmune-mediated mechanism. Absence
of a correlation between BAEP parameters and TSH and
free T3 levels, which are not related to autoimmunity, is
also a supportive finding that abnormal BAEP parameters
and also hearing systems may be related to autoimmunemediated mechanisms in patients with vitiligo.
Based on our results, melanin may play an important
role in the formation of the hearing system, maintenance
of hearing function, and modulation of auditory
stimulation in the inner ear. To date, the correlation
between autoimmunity and BAEP response was not
studied previously. The significant correlation between
autoimmune antibodies and BAEP responses may indicate
the presence of an underlying autoimmune mechanism.
However, multicenter studies are warranted to investigate
the effects of vitiligo on hearing disturbances and the
auditory system.
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